Eyecryl Phakic Iol.... May Be Another Option
Published 2023 - 41st Congress of the ESCRS
Reference: PO0969 | Type: Free paper | DOI: 10.82333/xqyx-qn38
Authors: Amr Al-Amin* 1
1Al-Mashreq Eye Center,Cairo,Egypt
Purpose
To assess the safety and efficacy of Eyecryl Phakic IOL to treat myopia.
Setting
Methods
Participants: Sixty-nine eyes of 46 patients with myopia ranging from -3.00 to -25.00 D were included in this study
Evaluation of Uncorrected Visual Acuity (UCVA), refraction, best spectacle corrected visual acuity (BSCVA), adverse events, operative and postoperative complications, subjective assessment and symptoms.
Results
The mean follow-up was 12.35 ± 6.13 (SD) months. At the last visit, 49.20% of eyes had 20/ 20 or better UCVA compared to preoperative 20/20 or better BSCVA of 31.9% of eyes; 69.23% of eyes had postoperative UCVA better than or equal to preoperative BCVA. The mean manifest refractive cylinder was 1.93±1.21D at baseline and 1.00 ± 0.92 D postoperatively. The mean manifest refraction spherical equivalent (MRSE) was -11.70 ± 4.24 D preoperatively and -0.69 ± 1.13 D postoperatively. A total of 69.8% of eyes were within ±0.5 D of the predicted MRSE; 84.1% were within ±1.0 D, and 88.90% were within ±2.0 D. BCVA of 20/20 or better was achieved in 64.6% of eyes postoperatively, compared to 31.9% preoperatively. Mean improvement in BCVA was one line
Conclusions
Implantation of Eyecryl Phakic IOL for the correction of myopia was a safe procedure with good visual and refractive results from the early postoperative period to 1 year. Long-term follow-up is required to confirm the long-term safety of this implant